The announcement of a lead drug candidate typically signals a positive development in a biotech company's pipeline, which can be viewed favorably by investors. The initiation of preclinical development suggests progress, although it is still early in the drug development process. This news may lead to increased investor confidence in Enveric Biosciences' future prospects, potentially causing a short-term positive impact on the stock price.